Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting ...

Visit the Investors and Media section of Mirum's corporate website for webcast links and additional information. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases ...

Background/Aim: To determine the roles of gastroesophageal acid reflux (GER) and esophageal dysmotility on typical and atypical GERD symptoms. Methods: Two hundred thirty-six patients (159 females ...

Outcomes are compared with 6-month outcomes after anterior 180° partial fundoplication, and sham procedures from trials of endoscopic therapies. No sham-controlled trial of EsophyX TIF procedure ...